基于“泻责之脾,痛责之肝”理论探讨腹泻型肠易激综合征的中医治疗Exploring the traditional Chinese medicine treatment of irritable bowel syndrome with predominant diarrhea based on the theory of "diarrhea results from the spleen, pain results from the liver"
朱沿帝,李一桐,毛堂友,谢春娥
摘要(Abstract):
腹泻型肠易激综合征(irritable bowel syndrome with predominant diarrhea, IBS-D)以腹痛与腹泻反复发作为特征。现代研究将IBS-D的发病机制指向脑-肠轴失调、内脏高敏感、肠道微生态紊乱与黏膜低度炎症等多系统失调。中医据《医方考》“泻责之脾,痛责之肝;肝责之实,脾责之虚”之旨,认为该病以“肝郁脾虚,虚实错杂”为关键病机,这与IBS-D多系统、多机制致病的现代研究相吻合。该文从“泻责之脾,痛责之肝”理论入手,联合脑-肠轴失调、肠道菌群失调等现代机制,综合论述IBS-D的发病机制,从而探讨IBS-D的治疗当以“抑木扶土,肝脾同治”为主要原则,旨在讨论“泻责之脾,痛责之肝”理论指导下运用痛泻要方为代表的方药体系治疗IBS-D的可行性,为IBS-D的临床治疗提供新的思路与视角。
关键词(KeyWords): 腹泻型肠易激综合征;泻责之脾,痛责之肝;脑-肠轴;抑木扶土
基金项目(Foundation): 深圳市中医临床医学研究中心临床研究开放课题项目(No:LCYSSQ20220823091203008);; 深圳市基础研究专项(自然科学基金)面上资助项目(No:JCYJ20240813153504007);; 北京市自然科学基金面上项目(No:7242232);; 深圳市宝安区中医院创新转化项目(No:2024CZZHZD02)
作者(Author): 朱沿帝,李一桐,毛堂友,谢春娥
参考文献(References):
- [1] 中华医学会消化病学分会胃肠功能性疾病协作组,中华医学会消化病学分会胃肠动力学组.2020年中国肠易激综合征专家共识意见[J].中华消化杂志,2020,40(12):803-818.
- [2] Bonetto S,Fagoonee S,Battaglia E,et al.Recent advances in the treatment of irritable bowel syndrome[J].Pol Arch Intern Med,2021,131(7-8):709-715.
- [3] Takeoka A,Kimura T,Hara S,et al.Prevalence of irritable bowel syndrome in Japan,China,and South Korea:an international cross-sectional study[J].J Neurogastroenterol Motil,2023,29(2):229-237.
- [4] Sebastián Domingo JJ.Irritable bowel syndrome[J].Med Clin,2022,158(2):76-81.
- [5] Chen J,Lan HB,Li CM,et al.Gut microbial signatures of patients with diarrhea-predominant irritable bowel syndrome and their healthy relatives[J].J Appl Microbiol,2024,135(6):lxae118.
- [6] Zhao YC,Zhu SX,Dong YL,et al.The role of gut microbiome in irritable bowel syndrome:implications for clinical therapeutics[J].Biomolecules,2024,14(12):1643.
- [7] Rettura F,Lambiase C,Tedeschi R,et al.Mucoprotectants and gut barrier:mechanisms of action and clinical applications in IBS.Is there a possible role?[J].Front Pharmacol,2025,16:1538791.
- [8] Marano G,Traversi G,Pola R,et al.Irritable bowel syndrome:a hallmark of psychological distress in women?[J].Life,2025,15(2):277.
- [9] Ray G,Ghoshal UC.Epidemiology of disorders of the gut-brain interaction:an appraisal of the Rome Ⅳ criteria and beyond[J].Gut Liver,2024,18(4):578-592.
- [10] Crocetta A,Giannelou MA,Benfante A,et al.Linking psychological stress to epigenetic regulation via the gut-liver-brain axis in irritable bowel syndrome and metabolic dysfunction-associated fatty liver disease[J].Livers,2025,5(3):43.
- [11] Shin AS,Xing Y,Waseem MR,et al.Microbiota and short chain fatty acid relationships underlie clinical heterogeneity and identify key microbial targets in irritable bowel syndrome(IBS)[J].Sci Rep,2025,15(1):35375.
- [12] Aggeletopoulou I,Triantos C.Microbiome shifts and their impact on gut physiology in irritable bowel syndrome[J].Int J Mol Sci,2024,25(22):12395.
- [13] Mayer EA,Ryu HJ,Bhatt RR.The neurobiology of irritable bowel syndrome[J].Mol Psychiatry,2023,28(4):1451-1465.
- [14] 焦瑶,陈慧慧,张烨,等.痛泻安肠方治疗腹泻型肠易激综合征肝郁脾虚证随机对照、双盲双模拟的临床研究[J].中华中医药杂志,2024,39(12):6910-6915.
- [15] Zhang QW,Yang MJ,Liao CY,et al.Atractylodes macrocephala Koidz polysaccharide ameliorates DSS-induced colitis in mice by regulating the gut microbiota and tryptophan metabolism[J].British J Pharmacology,2025,182(7):1508-1527.
- [16] Chen L,Chang XB,Wu CT,et al.Polysaccharide extracted from Atractylodes macrocephala improves the spleen deficiency constipation in mice by regulating the gut microbiota to affect the 5-HT synthesis[J].Neurogastroenterology Motil,2024,36(10):e14875.
- [17] Liu T,Lei C,Huang QH,et al.Hesperidin and fecal microbiota transplantation modulate the composition of the gut microbiota and reduce obesity in high fat diet mice[J].Diabetes Metab Syndr Obes,2024,17:3643-3656.
- [18] Park HY,Yu JH.Hesperidin enhances intestinal barrier function in Caco-2 cell monolayers via AMPK-mediated tight junction-related proteins[J].FEBS Open Bio,2023,13(3):532-544.
- [19] Li XS,Li H,Wang TT,et al.Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type Ⅰ allergy[J].Pharm Biol,2022,60(1):1224-1236.
- [20] Liang RF,Ge WJ,Song XM,et al.Paeoniflorin alleviates anxiety and visceral hypersensitivity via HPA axis and BDNF/TrkB/PLCγ1 pathway in maternal separation-induced IBS-like rats[J].Curr Mol Pharmacol,2024,17:e18761429280572.
- [21] Ke W,Wang YF,Huang SY,et al.Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a[J].Heliyon,2022,8(12):e12312.
- [22] 张薇,葛文静,王慧森,等.痛泻要方加减引经药防风对肠易激综合征大鼠水液代谢和5-HT系统的调控作用[J].中国实验方剂学杂志,2020,26(11):56-62.
- [23] 赵丹阳,杨倩,李佃贵,等.柴胡疏肝散加减治疗腹泻型肠易激综合征35例临床观察[J].湖南中医杂志,2017,33(1):10-12.
- [24] Tan X,Pei W,Xie C,et al.Tongxie Anchang Decoction relieves visceral hypersensitivity in diarrhea-predominant irritable bowel syndrome rats by regulating the NGF/TrkA signaling pathway[J].Evid Based Complement Alternat Med,2021,2021:6679348.
- [25] 袁亚利,谢春娥,李军祥,等.痛泻安肠方对肠易激综合征小鼠短链脂肪酸代谢及Th1/Th2细胞免疫平衡的影响[J].中国中医急症,2024,33(3):424-428.
- [26] 焦瑶,陈慧慧,毛堂友,等.痛泻安肠方对肠易激综合征患者粪便代谢组学及内脏高敏感的影响[J/OL].辽宁中医杂志,1-15[2026-08-20].https://link.cnki.net/urlid/21.1128.R.20250805.1711.064.